York-based ACM-Pivotal, formerly Pivotal Laboratories, which provides clinical trials services to the pharmaceutical and biotech industries, has been acquired by its US counterpart for an undisclosed sum.
Following a management buy out in 2005, Pivotal Laboratories and US-based ACM Medical Laboratories formed an alliance to extend their global capabilities and have been operating as ACM-Pivotal for the past three years.
This deal now formalises the acquisition of the European side of the business by ACM Medical Laboratories, securing the long-term future of the company in York.
The new organisation has been re-branded as ACM Global Central Laboratory. The company offers its services in more than 60 countries worldwide and performs over 12 million tests every year spanning all medical disciplines, including pathology, microbiology, flow cytometry and pharmacogenomics.
Some 38 people are employed at the laboratory’s facilities at Clifton Moor, York and it is expected that the company will be recruiting in order to meet increased demand.
Jerry Boxall, md of Pivotal Laboratories said: ‘This is a very exciting development for us. Building on the success of our alliance over the past four years, this allows our unified group to continue its impressive record of growth and to enhance our service offering on a global basis. In just ten years we‘ve taken Pivotal Laboratories from a small start-up to a well-respected international organisation and the deal is great news to the York economy in a particularly difficult time.’
Art Glenz, president and ceo of ACM Medical Laboratory said: ‘The complete integration of the two companies places us in a stronger position. This was the next logical step in our relationship. We anticipate continued growth in the global clinical trials market.’